Showing results (531-540 of 626) with videos related to
Sort By:
Pageof 63
The Journal of Allergy and Clinical Immunology|October 4, 2022
Safety of upadacitinib in moderate-to-severe atopic dermatitis: An integrated analysis of phase 3 studiesEmma Guttman-Yassky, Jacob P Thyssen, Jonathan I Silverberg, et al.Dermatology and Therapy|June 23, 2025
Two-Year Efficacy and Safety of Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Long-Term Extension (ADjoin)Emma Guttman-Yassky, Stephan Weidinger, Eric L Simpson, et al.Dermatology and Therapy|June 15, 2023
Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 StudyAmy S Paller, Carsten Flohr, Lawrence F Eichenfield, et al.Bioorganic & Medicinal Chemistry Letters|July 28, 2005
Discovery and structure-activity relationships of novel sulfonamides as potent PTP1B inhibitorsChristopher P Holmes, Xianfeng Li, Yijun Pan, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|August 1, 2024
International consensus on methotrexate dosing for patients with atopic dermatitis: An eDelphi studyAnouk G M Caron, Astrid M van Huizen, Annelie A H Musters, et al.Bioorganic & Medicinal Chemistry Letters|March 29, 2008
PTP1B inhibitors: synthesis and evaluation of difluoro-methylenephosphonate bioisosteres on a sulfonamide scaffoldChristopher P Holmes, Xianfeng Li, Yijun Pan, et al.The British Journal of Dermatology|August 14, 2020
Autosomal recessive hypotrichosis with loose anagen hairs associated with TKFC mutationsA Onoufriadis, A Cabezas, J C F Ng, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|September 5, 2023
Real-world clinical, psychosocial and economic burden of atopic dermatitis: Results from a multicountry studyKilian Eyerich, Melinda J Gooderham, Juan Francisco Silvestre, et al.Dermatology and Therapy|June 17, 2026
A Durability Index for Atopic Dermatitis: Indirect Comparison of Lebrikizumab, Dupilumab, and Tralokinumab in Maintaining Efficacy Under Variable Treatment AdherenceJonathan I Silverberg, Alan D Irvine, Peter Foley, et al.The British Journal of Dermatology|December 4, 2019
What is the evidence for interactions between filaggrin null mutations and environmental exposures in the aetiology of atopic dermatitis? A systematic reviewH Blakeway, V Van-de-Velde, V B Allen, et al.Pageof 63